Zacks Investment Research
06 Oct 2025, 14:56 UTC · 49w ago
Verdict
Headline takes no side. We score ESPR +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Esperion Therapeutics reached a settlement with Dr. Reddy’s Laboratories to prevent the launch of generic versions of Nexletol and Nexlizet in the U.S. before April 19, 2040.
More positive than 91% of claims this week
The settlement with Dr. Reddy's resolves all remaining disputes concerning the validity or infringement of U.S. Patent No. 7,335,799.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
Esperion previously reached similar settlement agreements with Micro Labs USA, Hetero USA, and Accord Healthcare, also delaying generic Nexletol until 2040.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reached a settlement preventing generic competition for its drugs until 2040, leading to a 13.8% stock price increase.
More negative than 71% of ticker scores this week
The company agreed to delay the launch of generic versions of Nexletol and Nexlizet in the US until 2040.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
−3.6%
Price is moving against the score
$3.18 vs $3.30 close before publication (Oct 3) · not market-adjusted
ESPR chart →
